Fig. 5

Overview of accelerated review and approval process for innovative drugs in China from 2020 to 2023. a Number of cases agreed or disagreed for inclusion under the Breakthrough Therapy program from 2020 to 2023. b Distribution of indication areas for drugs agreed for inclusion under Breakthrough Therapy program in the year of 2023. c Number of drugs conditionally approved and transitioned to regular approval from 2020 to 2023. d Distribution of indications for conditionally approved drugs from 2020 to 2023. e Number of drug registration applications under the Prioritized Evaluation and Approval procedure from 2020 to 2023. f Distribution of indications for drug registration applications under the Prioritized Evaluation and Approval procedure from 2020 to 2023.^{95,96,97,98,99}